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Hien Duong,1 Steven Andresen,1 Ronald Sobecks,1 Robert Dean,1 Brad Pohlman,1
Matt Kalaycio,1 Edward A. Copelan1Patient readmission within 30 days from discharge has been perceived by the Centers for Medicare and Med-
ical Services as an indicator of poor healthcare quality for specific high-cost medical conditions. Patients who
undergo allogeneic hematopoietic cell transplantation (allo-HCT) are often being readmitted. Our study
identified the risk factors for 30-day readmission among 618 adult recipients of myeloablative allo-HCT
from 1990 to 2009. Two hundred forty-two (39%) of 618 patients (median age 5 42 years [range: 18-66])
were readmitted a median of 10 days (range: 1-30) from their hospital discharge. Median duration of read-
mission was 8 days (range: 0-103). Infections (n 5 68), fever with or without identified source of infection
(n 5 63), gastrointestinal complications (n 5 44), graft-versus-host disease (GVHD) (n 5 38), and other
reasons (n 5 29) accounted for 28%, 26%, 18%, 16%, and 12% of readmissions, respectively. During their
index admission, patients who were subsequently readmitted had more documented infections (P\.001),
higher hematopoietic cell transplantation comorbidity index (HCT-CI) (P \ .01), total body irridiation
(TBI)-based conditioning (P\.001), unrelated donor (P\.001), and peripheral stem cell (P 5 .014) trans-
plantation. In multivariable analysis, HCT-CI (odds ratio [OR] 5 1.78; 95% confidence interval [CI], 1.25-
2.52), TBI-based preparative regimen (OR 5 2.63; 95% CI, 1.67-4.13), and infection during admission for
allo-HSCT (OR 5 2.00; 95% CI, 1.37-2.92) predicted 30-day readmission. Thirty-day readmission itself
was an independent predictor of all-cause mortality (hazard ratio [HR]Adj 5 1.66; 95% CI, 1.36-2.10).
Our data emphasize the importance of a risk-standardized approach to 30-day hospital readmission if it is
used as a quality-of-care metric for bone marrow transplantation.
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Hospital readmission shortly after index hospitali-
zation increases healthcare costs. Approximately 20%
of Medicare beneficiaries are readmitted within
30 days of hospital discharge, and about 90% of these
readmissions are unplanned [1-3]. The 30-day read-
mission rate has been chosen as a quality care metric1Taussig Hematologic Oncology and Blood Disorders,
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(www.qualitynet.org). Data on 30-day readmission
rates for a number of leading causes of hospitalization
(eg, pneumonia, heart failure) reveal substantial het-
erogeneity across the United States and are thought
to reflect differences in quality of care. These differ-
ences have led to calls for nationwide quality improve-
ment efforts [4,5]. Risk-standardized readmission and
mortality rates vary among older patients with
pneumonia from 14% to 27% and from 10% to
12%, respectively [6]. The nationwide rate of 30-day
readmission for patients with heart failure reaches
29%, and the risk-standardized mortality rate is up
to 17% [3,7-9]. Risk factors predicting 30-day hospital
readmissions among patients above 65 years old in-
clude demographic (such as age, male gender, African
American race), medical (comorbid conditions such as
heart failure, vasculopathies, diabetes, renal failure,
end-stage liver disease, chronic lung disease, solid
organ malignancies, lymphomas, and leukemias), and
Biol Blood Marrow Transplant 18:874-880, 2012 875Risk Factors for 30-Day Hospital Readmissionhealthcare features (such as havingMedicare insurance
and being discharged to a skilled nursing facility) [10].
In a study conducted among adults admitted to a gen-
eral medicine service, Charlson comorbidity index,
SF12 physical component score, insurance status,
social support, previous admissions within a year,
and length of hospital stay during index admission
were all found to be independent predictors for early
readmissions [11]. Many readmissions might be pre-
vented by the use of alternative nonhospital services, as
most readmissions are because of chronic medical con-
ditions [7,12]. Transitional care programs have thus
been proposed to improve hospital discharge planning
for the patients at highest risk for readmissions,
including those requiring continuous complex medical
care [13-15]. On the other hand, some studies have
demonstrated a correlation between increased use of
hospital resources and lower patient mortality rate
[8,16]. Mortality was found to be lower among
patients with heart failure who were readmitted within
30 days of discharge compared with those who were
not [5]. Successful inpatient care with low in-hospital
mortality among patients with heart failure may
lead to a larger living patient population at risk for
readmission [5].
Patients treated with allogeneic hematopoetic cell
transplantation (allo-HCT) have high rates of hospital
readmission [17]. However, neither the factors pre-
dicting 30-day readmission nor the impact of readmis-
sion on overall survival (OS) has been examined in the
context of allo-HCT. We designed this single-center
retrospective study to identify the reasons and risk
factors for 30-day readmission among the recipients
of myeloablative allo-HCT. We also evaluated the
impact of those factors and of readmission on survival.MATERIALS AND METHODS
Patients and Setting
A total of 748 adult patients underwent allo-HCT
between 1990 and 2009 at the Cleveland Clinic
Taussig Cancer Institute. Of these, 121 died during
the transplant admission and 9 died within 30 days of
discharge without a readmission. These 130 patients
were excluded, and the analysis was based on the
remaining 618 patients. All patients received their allo-
grafts in an inpatient bonemarrow transplant unit. The
patients were kept hospitalized until they became free
of fever, infections, or other serious complications,
and their absolute neutrophil count recovered above
500 cells/mL. All patients received discharge teaching
instructions on common complications after allo-
HCT, and the appropriate follow-up appointments
were arranged by individually assigned transplant co-
ordinators upon their hospital discharge. Information
on hospital readmissions, demographic, and clinicalpatient characteristics was collected retrospectively
from the Unified Transplant Database (UTD) at the
Cleveland Clinic Taussig Cancer Institute.
Information on readmissions including the reasons
for readmissions were captured and collected prospec-
tively from patients’ individual transplant coordinators
and/or from on-call physician documentations in
either electronic or paper charts. In addition, further
detailed information was also collected during daily in-
patient rounds by our dedicated UTD data-collecting
personnel. We collected and analyzed the following
variables: patient age, gender, race, type of hematologic
malignancy (myeloid, lymphoid, or other), pretrans-
plantation disease status (remission or no remission),
number of prior chemotherapy regimens, prior radia-
tion treatment, hematopoietic cell transplantation-
specific comorbidity index (HCT-CI), type of
preparative regimen, source of hematopoietic cells,
donor type, time until neutrophil count recovery, in-
fection and acute graft-versus-host disease (aGVHD)
during hospital stay, and length of hospital stay.
Myeloid malignancies were acute myelogenous leuke-
mia, myelodysplastic syndromes, myeloproliferative
neoplasms, and chronic myelogenous leukemia. Lym-
phoid malignancies included acute lymphoblastic
leukemia, biphenotypic leukemia, lymphomas, multi-
ple myeloma, and plasma cell leukemia. Other condi-
tions requiring allo-HCT included aplastic anemia
and paroxismal nocturnal hemoglobulinemia. Infec-
tions were defined as any documented bacterial, viral,
or fungal infectionswith isolation of a specificmicroor-
ganism. The diagnosis of pneumonia was made when
both radiologic and clinical findings of pneumonia
were present. This study was approved by the
Cleveland Clinic institutional review board.
Statistical Analysis
Study variables were compared between the pa-
tients who were readmitted and those who were not.
Chi-square and Wilcoxon rank sum tests were used
to compare categoric and continuous variables, respec-
tively. Univariate and multivariable risk factors for
readmission were assessed using logistic regression
analysis. As multiple preparative regimens were
employed, recursive partitioning analysis was used to
categorize these regimens. Recursive partitioning
analysis indicated that the most important aspect of
the preparative regimen associated with readmission
was whether or not it included total body irridiation
(TBI). Multivariable analysis was performed using
a stepwise procedure with a variable entry criterion
of P\ .10 and a variable retention criterion of P\
.05. Model-based probabilities of readmission were
calculated for all combinations of variables in the final
multivariable logistic model. The number of risk fac-
tors was calculated for each patient, and the percentage
readmitted was compared relative to the number of
Table 1. Patient Characteristics
Variable
Readmission
(n 5 242)
Not Readmitted
(n 5 376) P Value
Age, median 42 (18-66) 40 (18-68) .32
Male 130 (54) 325 (53) .65
Race
Caucasian 215 (89) 342 (91) .27
African American 23 (10) 24 (6)
Other 4 (2) 10 (3)
Malignancy type
Myeloid 161 (67) 275 (73) .06
Lymphoid 73 (30) 83 (22)
Other* 8 (3) 18 (5)
Disease status
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Survival after the transplantation discharge was esti-
mated using the Kaplan-Meier method and compared
between patients who were readmitted within 30 days
of discharge and those whowere not using the log-rank
test. Univariate and multivariable risk factors for mor-
tality were assessed using Cox proportional hazards
analysis. Multivariable analysis was done using a step-
wise procedure as described earlier. Analyses were
done using SAS software (SAS Institute, Inc., Cary,
NC). All statistical tests were 2 sided, and P \ .05
was used to indicate statistical significance.Active disease 141 (58) 206 (55) .40
Remission 101 (42) 170 (45)
Prior chemoRx
0/hydrea§ 23 (9) 50 (13) .06
1-2 159 (66) 257 (69)
$3 60 (25) 66 (18)
Prior RT 28 (12) 34 (9) .31
HCT-CI‡
High/intermediate 150 (64) 177 (49)
Low 84 (36) 187 (51)
TBI-containing prep 64 (26) 40 (11) <.001
Stem cell source
Bone marrow 203 (84) 344 (92) .014
Peripheral stem cell cord 31 (13) 24 (6)
Cord 8 (3) 8 (2)
Donor, unrelated 112 (46) 113 (30) <.001
Infection† 99 (41) 80 (21) <.001
aGVHD, grade II-IV† 40 (17) 52 (14) .36
Length of stay, days† 32 (17-106) 31 (18-91) .96
Days to ANC >500 15 (6-66) 16 (7-75) .10
Days to readmission 10 (1-30) —
ANC indicates absolute neutrophil count.
Note: Values in brackets correspond to percentage or range for median
values.
*Other: aplastic anemia, peroxismal nocturnal hemoglobulinemia.
†During index admission for allo-HCT.
‡Twenty subjects had missing HCT-CI data.
§Fifty-three subjects had no prior chemotherapy: chronic myeloid leuke-
mia (n 5 17), aplastic anemia (n 5 16), myelodysplastic syndromes/
chronic myelomonogotic leukemia (n 5 9), secondary acute myeloge-
nous leukemia (n 5 4), myelofibrosis (n 5 4), myeloproliferative disor-
ders (n 5 1), paroxismal nocturnal hemoglobulinemia (n 5 1), and Ph+
acute lymphoblastic leukemia (n 5 1).RESULTS
Patient Characteristics
A total of 242 of the 618 allograft patients (39%)
were readmitted within 30 days after hospital dis-
charge following their index hospitalization for allo-
HCT. Baseline characteristics of both the readmitted
and the not readmitted subsets are summarized in
Table 1. Compared with the group that was not read-
mitted, the readmitted group was enriched for patients
who had higher HCT-CI (64% versus 49%, P\ .01),
TBI-containing preparative regimens (26% versus
11%, P\ .001), unrelated donors (46% versus 30%,
P\ .001), peripheral blood stem cell source (13% ver-
sus 6%, P5 .014), and documented infectious compli-
cations (41% versus 21%, P\ .001) during their index
admission for transplantation. Grade 2 or greater
aGVHD developed in 15% of patients receiving allo-
HCT. Median neutrophil count recovery was 16
days (range: 6-75) and median length of hospital stay
32 days (range: 17-106) for all patients. Median days
from hospital discharge to readmission were 10 (range:
1-30), and the median duration of the readmission
hospital stay was 8 days (range: 0-103).
Reasons for 30-Day Hospital Readmission
Four major reasons for hospital readmission within
30 days were identified following myeloablative allo-
HCT, including 68 patients with identified infections
(28%); 63 patientswith fever (26%)without identifiable
infection; 44 patients with gastrointenstinal complica-
tions such as nausea, vomiting, or diarrhea (18%); and
38 patients with GVHD (16%). Less common reasons
included cardiac (n 5 7), respiratory (5), neurologic
(n 5 5), and renal or electrolyte abnormalities (n 5 4).
Rare reasons for hospital readmission included throm-
boembolic events, disease relapse, and graft rejection.
Several patients were readmitted for 2 or more reasons,
accounting for 11% of all readmissions.
Risk Factors for Readmission
In univariate analysis (Table 2), patients with lym-
phoid malignancies were more likely to be readmittedwithin 30 days of discharge compared with those with
myeloid malignancy (odds ratio [OR] 1.50; 95% confi-
dence interval [CI], 1.04-2.17; P5 .031). An increased
number of prior chemotherapy regimens was associ-
ated with a significantly higher readmission rate (OR
1.20; 95% CI, 1.05-1.37; P 5 .007). In addition,
patients with higher HCT-CI (OR 1.89; 95% CI,
1.35-2.64; P\ .001) and those who received a TBI-
containing preparative regimen (OR 3.02; 95% CI,
1.96-4.66; P \ .001) during their allo-HCT were
found to have a greater readmission risk. Use of an un-
related donor (OR 2.0; 95% CI, 1.43-2.8; P\ .001)
was also associated with higher risk of 30-day readmis-
sion. Patients with infectious complications during
their index admission were at higher risk for readmis-
sion (OR 2.56; 95% CI, 1.79-3.66; P \ .001). In
multivariable analysis, only 3 variables remained
significant in their association with higher risk of
Table 2. Risk Factors for Readmission: Logistic Regression Analysis
Variable
Univariable Multivariable
OR 95% CI P Value OR 95% CI P Value
Age
Per 10 year increase 1.06 0.92-1.22 .42 — — —
Gender
Male/female 1.08 0.78-1.49 .65 — — —
Race
African American/other 1.54 0.85-2.80 .16 — — —
Malignancy type
Lymphoid/myeloid 1.50 1.04-2.17 .031 — — —
Other/myeloid 0.76 0.32-1.78 .53
Disease status
Active/remission 1.15 0.83-1.60 .40 — — —
Number of prior chemoRx
Per 1 regimen increase 1.20 1.05-1.37 .007 — — —
Prior RT
Yes/No 1.32 0.78-2.23 .31 — — —
HCT-CI
High+Int/Low 1.89 1.35-2.64 <.001 1.78 1.25-2.52 .001
Prep regimen
TBI/No TBI 3.02 1.96-4.66 <.001 2.63 1.67-4.13 <.001
Donor type
Unrelated/related 2.00 1.43-2.80 <.001 — — —
Infection*
Yes/No 2.56 1.79-3.66 <.001 2.00 1.37-2.92 <.001
aGVHD*
Per 1 grade increase 1.13 0.94-1.35 .19 — — —
Days to ANC >500
Per 1 day increase 0.98 0.95-1.01 .16 — — —
Length of stay, days*
Per 1 week increase 1.05 0.96-1.15 .26 — — —
ANC indicates absolute neutrophil count.
*During index admission for allo-HCT.
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preparative regimen (OR 2.63; P\ .001), and infection
during index admission for allo-HCT (OR 2.0; P\
.001).
Model-based probabilities for readmission were
calculated from 3 risk factors identified by multivari-
able logistic regression analysis (Table 3). The lowest
risk for readmission (24%) was among the patients
with low HCT-CI who received non-TBI-based regi-
mens and had no documented infection during index
transplantation admission. In contrast, the greatest
risk for readmission (75%) was observed in the pres-
ence of all 3 risk factors; those patients with high
HCT-CI who received a TBI-based regimen and
had infectious complications during their hospital
stay. Estimated readmission percentages in the pres-
ence of 0, 1, 2, or all 3 risk factors demonstrated step-
wise increments with 23.3%, 38.5%, 54.1%, and
76.7% rates of readmission, respectively (P\ .001).Table 3. Predicted Risk of 30-Day Readmission
Prep Infection
HCT-CI
Low Intermediate/High
No TBI No 24.0% 35.9%
Yes 38.7% 52.9%
TBI No 45.3% 59.5%
Yes 62.4% 74.7%Patients’ Survival and Risk Factors for
Postdischarge Mortality
OS was significantly worse among patients who
were readmitted within 30 days after hospital dis-
charge following myeloablative allo-HCT (Figure 1).
Median survival for patients with and without readmis-sion was 10.0 months and 42.8 months, respectively
(P\ .001).
Univariate survival analysis identified 30-day read-
mission (hazard ratio [HR] 1.81; 95% CI, 1.47-2.23;
P \ .001), patient age at transplantation (HR 1.11;
95% CI, 1.01-1.22; P 5 .035), disease status (HR
1.41; 95% CI, 1.15-1.74, P 5 .001), number of prior
chemotherapy regimens (HR 1.14; 95% CI, 1.05-
1.23; P 5 .002), HCT-CI (HR 1.77; 95% CI, 1.42-
2.20; P \ .001), unrelated donor types (HR 1.27;
95% CI, 1.02-1.56; P 5 .029), infections (HR 1.32;
95% CI, 1.06-1.65; P 5 .012), aGVHD (HR 1.20;
95% CI, 1.07-1.33; P 5 .001), and length of hospital
stay (HR 1.18; 95%CI, 1.12-1.24; P\ .001) during in-
dex admission for transplantation as significant risk
factors for all-cause mortality (Table 4). In the ad-
justed Cox analysis, however, only 5 of these factors
Figure 1. Survival by readmission within 30 days of discharge.
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days: 30-day readmission (HR 1.66; 95% CI, 1.36-
2.10; P \ .001), pretransplantation disease status
(HR 1.42; 95% CI, 1.14-1.78; P 5 .002), number of
prior chemotherapy regimens (HR 1.13; 95% CI,
1.04-1.22; P 5 .004), higher HCT-CI (HR 1.54;
95%CI, 1.23-1.93; P\ .001), and length of index hos-
pitalization (HR 1.16; 95% CI, 1.10-1.22; P\ .001)
(Table 4). Additionally, among the subset of patients
who were readmitted, we identified that mortalityTable 4. Risk Factors for Postdischarge Mortality: Cox Regression
Variable
Univariable
HR 95% CI
30-day readmission
Yes/No 1.81 1.47-2.23
Age
Per 10 year increase 1.11 1.01-1.22
Gender
Male/female 1.22 0.99-1.50
Race
African American/other 1.20 0.83-1.72
Malignancy type
Lymphoid/myeloid 1.22 0.97-1.52
Other/myeloid 0.35 0.16-0.78
Disease status
Active/remission 1.41 1.15-1.74
Number of prior chemoRx
Per 1 regimen increase 1.14 1.05-1.23
Prior RT
Yes/No 1.43 1.04-1.95
HCT-CI
High + Int/Low 1.77 1.42-2.20
Prep regimen
TBI/no TBI 1.08 0.82-1.41
Donor type
Unrelated/related 1.27 1.02-1.56
Infection*
Yes/No 1.32 1.06-1.65
aGVHD*
Per 1 grade increase 1.20 1.07-1.33
Days to ANC >500
Per 1 day increase 1.01 0.99-1.02
Length of stay, days*
Per 1 week increase 1.18 1.12-1.24
*During index admission for allo-HCT.risk increases with longer readmission (HR 1.07,
95% CI 1.01-1.13, P 5 .025, per 7 day increase in
length of readmission).DISCUSSION
Myeloablative allo-HCT is potentially curative for
patients with various hematologic malignancies. How-
ever, it is associated with substantial posttransplanta-
tion morbidity and mortality [18]. Patients receiving
allo-HCT remain at risk for serious complications
such as infections, GVHD, and disease relapse for
a prolonged period following initial hospital discharge.
These complications may require hospital readmis-
sions for further inpatient management. Investigators
from City of Hope evaluated the readmission pattern
in 100 adult patients following autologous or alloge-
neic stem cell transplantation for various hematologic
malignancies and reported in every patient at least 1
unscheduled readmission within 6 months of dis-
charge. They found significantly higher rates of read-
mission and prolonged hospital stays in allogeneic
transplant recipients compared with those undergoing
autologous transplantation. The most common com-
plications were fever/infections, followed by gastroin-
testinal problems and GVHD. Up to 80% of the
patients had infectious complications, which wereAnalysis
Multivariable
P Value HR 95% CI P Value
<.001 1.66 1.36-2.10 <.001
.035 — — —
.06 — — —
.33 — — —
.09 — — —
.011
.001 1.42 1.14-1.78 .002
.002 1.13 1.04-1.22 0.004
.025 — — —
<.001 1.54 1.23-1.93 <.001
.58 — — —
.029 — — —
.012 — — —
.001 — — —
.32 — — —
<.001 1.16 1.10-1.22 <.001
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have found a similar pattern of readmission within
the 30 days of discharge. Uniformity of readmission
patterns across geographic regions favors the notion
that the frequency of readmission is not specific for
individual transplant centers but is rather related to
the allo-HCT patient population.
We identified 3 risk factors predictive for 30-day
hospital readmissions including HCT-CI, TBI-con-
taining regimens, and infections during index trans-
plant admission. Two of these risk factors (infections
and use of TBI) are potentially modifiable, but preven-
tion of infections during index admission may be par-
ticularly challenging for a number of reasons. First, the
increased rate of infectious complications in myeloa-
blative allo-HCT recipients is because of enhanced
susceptibility to various pathogens up to a year follow-
ing allo-HCT until full immune reconstitution is
achieved [19-21]. Second, discharging allo-HCT
recipients with indwelling central venous catheters re-
mains a common institutional policy across transplant
centers, including ours. Although this practice facili-
tates frequent outpatient blood product transfusions
in the early posttransplantation period, it may increase
the risk for line infections. Third, in order to control
GVHD, allograft recipients require prolonged immu-
nosuppressive therapy, which itself leads to increased
susceptibility to infectious complications. Further-
more, the rate of infections is particularly high in pa-
tients who develop GVHD [22].
Because the risk of developing life-threatening in-
fections is higher for allo-HCT patients, our institu-
tional approach has been to require these patients to
reside within 1 hour of driving distance from the hos-
pital within first 100 days after allo-HCT. The pa-
tients are also expected to have 24-hour caregivers
and are instructed to notify their transplant nurse or
overnight/weekend coverage physician for any fever
$100.4 F in order to facilitate direct hospital admis-
sion to the bone marrow transplant unit. Such a low
threshold for readmission has been used to maximize
rapid detection and management of life-threatening
complications of allo-HCT. Although this strategy
may lead to increased rates of hospital readmissions
in patients with allo-HCT, it may also ensure the
best quality of care.
Although the type of preparative regimen had no
impact on patient survival, the use of TBI-containing
regimens was associated with higher rates of readmis-
sion. A recent large meta-analysis involving over
3000 patients from 18 trials compared the outcomes
of TBI/cyclophosphamide and busulfan/cyclophos-
phamide and demonstrated differences in types of
posttransplantation complications [23]. Because TBI-
containing regimens were associated with 30-day
readmission, but not the OS, it is possible that TBI-
induced complications manifested earlier leading tohigher rates of 30-day readmissions. This hypothesis,
however, will require further validation in independent
dataset(s).
As was expected, HCT-CI was strongly associated
with both 30-day readmissions and postdischargemor-
tality. In this regard, our data corroborates the findings
from other studies that consistently report increased
risks of readmissions in patients with underlying
chronic medical conditions [7,10-12]. A reasonable
strategy to minimize hospital readmissions because
of underlying chronic medical conditions would
involve scheduling early postdischarge outpatient
follow-ups with appropriate subspecialty physicians.
Model-based readmission probabilities calculated
based on the number of risk factors facilitate stratifica-
tion of patients according to their risk of 30-day post-
discharge readmission. According to our model, the
individuals at highest risk are those with high HCT-
CI who received a TBI-based regimen and who devel-
oped infectious complications during their index
admission. Identification of these patients before dis-
charge may help improve the quality of their outpa-
tient care and prevent complications by scheduling
closer follow-ups with their transplant physicians as
well as other specialists.
The study of heart failure patients across the U.S.
ranked and nonranked hospitals demonstrated that
ranked hospitals had more patient readmissions, but
less mortality, compared with nonranked hospitals,
emphasizing that readmissions and OS possibly
measure distinct quality metrics among heart failure
patients [11]. In contrast to patients with heart failure,
the correlation between 30-day readmission and
all-cause patient mortality in our study appears to be
specific for patients with allo-HCT. Our findings
support the notion that quality metrics are highly
disease-specific and therefore cannot be uniformly
generalized.
Although the length of index hospital stay for allo-
HCT was independently associated with overall
patient mortality, it was not found to be predictive
for 30-day readmissions in our study. Prolonged hos-
pitalization during admission for allo-HCT is gener-
ally because of serious complications, which could
have possibly resulted in poor OS for the patients in
this study.
One possible limitation of our study is its retro-
spective design with its inherent potential to introduce
the ascertainment bias. However, our Bone Marrow
Transplant Database was created independently from
this study and continuous data quality checking has
been set up to minimize potential bias.
In summary, 30-day hospital readmissions follow-
ing myeloablative allo-HCT was associated with poor
OS. The risk-stratification approach to patient read-
mission appears to be an essential component of the
quality-of-care metric among patients with allo-HCT.
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